New hope for rare bone cancer: trabectedin trial targets advanced disease

NCT ID NCT04305548

Recruiting now Disease control Sponsor: Italian Sarcoma Group Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests the drug trabectedin in 16 people aged 16 and older with advanced mesenchymal chondrosarcoma, a rare bone cancer that has spread or cannot be removed by surgery. Participants must have already tried at least one chemotherapy. The goal is to see if trabectedin can shrink tumors or slow the disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MESENCHYMAL CHONDROSARCOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

mesenchymal chondrosarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MESENCHYMAL CHONDROSARCOMA

Contacts and locations

Locations

Fondazione IRCSS Istituto Nazionale dei Tumori
RECRUITING

Milan, 20133, Italy
Fondazione del Piemonte per l'Oncologia IRCC Candiolo
RECRUITING

Candiolo, Torino, 10060, Italy
Istituti Fisioterapici Ospitalieri - Ospedale Regina Elena
RECRUITING

Roma, 00128, Italy
Istituto Ortopedico Rizzoli - Unit of Chemotherapy of Muscoloskeletal Tumors
RECRUITING

Bologna, 40136, Italy
Nuovo Ospedale di Prato
RECRUITING

Prato, Firenze, 59100, Italy
Ospedale Giaccone
RECRUITING

Palermo, Italy
Policlinico Universitario Campus Biomedico
NOT_YET_RECRUITING

Roma, RM, 00128, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.